BACKGROUND: Neutralizing antibodies (NAb) affect efficacy of interferon-beta (IFN-b) treatment in multiple sclerosis (MS) patients. NAbs evolve in up to 44% of treated patients, usually between 6-18 months on therapy. OBJECTIVES: To investigate whether early binding antibody (BAb) titers or different IFN-b biomarkers predict NAb evolution. METHODS: We included patients with MS or clinically isolated syndrome (CIS) receiving de novo IFN-b treatment in this prospective European multicenter study. Blood samples were collected at baseline, before and after the first IFN-b administration, and again after 3, 12 and 24 months on that therapy; for determination of NAbs, BAbs, gene expression of MxA and protein concentrations of MMP-9, TIMP-1, sTRAIL, CXCL-10 and CCL-2. RESULTS: We found that 22 of 164 (13.4%) patients developed NAbs during a median time of 23.8 months on IFN-b treatment. Of these patients, 78.9% were BAb-positive after 3 months. BAb titers ≥ 1:2400 predicted NAb evolution with a sensitivity of 74.7% and a specificity of 98.5%. Cross-sectionally, MxA levels were significantly diminished in the BAb/NAb-positive samples; similarly, CXCL-10 and sTRAIL concentrations in BAb/NAb-positive and BAb-positive/NAb-negative samples, respectively, were also diminished compared to BAb/NAb-negative samples. CONCLUSIONS: BAb titers reliably predict NAbs. CXCL-10 is a promising sensitive biomarker for IFN-b response and its abrogation by anti-IFN-b antibodies.
BACKGROUND: Neutralizing antibodies (NAb) affect efficacy of interferon-beta (IFN-b) treatment in multiple sclerosis (MS) patients. NAbs evolve in up to 44% of treated patients, usually between 6-18 months on therapy. OBJECTIVES: To investigate whether early binding antibody (BAb) titers or different IFN-b biomarkers predict NAb evolution. METHODS: We included patients with MS or clinically isolated syndrome (CIS) receiving de novo IFN-b treatment in this prospective European multicenter study. Blood samples were collected at baseline, before and after the first IFN-b administration, and again after 3, 12 and 24 months on that therapy; for determination of NAbs, BAbs, gene expression of MxA and protein concentrations of MMP-9, TIMP-1, sTRAIL, CXCL-10 and CCL-2. RESULTS: We found that 22 of 164 (13.4%) patients developed NAbs during a median time of 23.8 months on IFN-b treatment. Of these patients, 78.9% were BAb-positive after 3 months. BAb titers ≥ 1:2400 predicted NAb evolution with a sensitivity of 74.7% and a specificity of 98.5%. Cross-sectionally, MxA levels were significantly diminished in the BAb/NAb-positive samples; similarly, CXCL-10 and sTRAIL concentrations in BAb/NAb-positive and BAb-positive/NAb-negative samples, respectively, were also diminished compared to BAb/NAb-negative samples. CONCLUSIONS:BAb titers reliably predict NAbs. CXCL-10 is a promising sensitive biomarker for IFN-b response and its abrogation by anti-IFN-b antibodies.
Entities:
Keywords:
Binding antibody; CXCL-10; biomarker; clinically-isolated syndrome; drug resistance; interferon-beta; multicenter study; multiple sclerosis; myxovirus protein A; neutralizing antibody; sTRAIL
Authors: Antonio Bertolotto; Marco Capobianco; Maria Pia Amato; Elisabetta Capello; Ruggero Capra; Diego Centonze; Maria Di Ioia; Antonio Gallo; Luigi Grimaldi; Luisa Imberti; Alessandra Lugaresi; Chiara Mancinelli; Maria Giovanna Marrosu; Lucia Moiola; Enrico Montanari; Silvia Romano; Luigina Musu; Damiano Paolicelli; Francesco Patti; Carlo Pozzilli; Silvia Rossi; Marco Salvetti; Gioachino Tedeschi; Maria Rosaria Tola; Maria Trojano; Maria Troiano; Mauro Zaffaroni; Simona Malucchi Journal: Neurol Sci Date: 2013-12-29 Impact factor: 3.307
Authors: Harald Hegen; Indra Adrianto; Christopher J Lessard; Alban Millonig; Antonio Bertolotto; Manuel Comabella; Gavin Giovannoni; Michael Guger; Martina Hoelzl; Michael Khalil; Franz Fazekas; Joep Killestein; Raija L P Lindberg; Simona Malucchi; Matthias Mehling; Xavier Montalban; Dagmar Rudzki; Franz Schautzer; Finn Sellebjerg; Per Soelberg Sorensen; Florian Deisenhammer; Lawrence Steinman; Robert C Axtell Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-01-27
Authors: Delphine Bachelet; Signe Hässler; Cyprien Mbogning; Jenny Link; Malin Ryner; Ryan Ramanujam; Michael Auer; Poul Erik Hyldgaard Jensen; Nils Koch-Henriksen; Clemens Warnke; Kathleen Ingenhoven; Dorothea Buck; Verena Grummel; Andy Lawton; Naoimh Donnellan; Agnès Hincelin-Mery; Dan Sikkema; Marc Pallardy; Bernd Kieseier; Bernard Hemmer; Hans Peter Hartung; Per Soelberg Sorensen; Florian Deisenhammer; Pierre Dönnes; Julie Davidson; Anna Fogdell-Hahn; Philippe Broët Journal: PLoS One Date: 2016-11-02 Impact factor: 3.240
Authors: Edward Fox; Barbara Green; Clyde Markowitz; Ronald Murray; Andrew D Goodman; Stephen J Glenski; Pippa Loupe; Jo Nita Cogburn Journal: BMC Neurol Date: 2014-04-04 Impact factor: 2.474
Authors: Tamarah D de Jong; Saskia Vosslamber; Elise Mantel; Sander de Ridder; John G Wesseling; Tineke C T M van der Pouw Kraan; Cyra Leurs; Harald Hegen; Florian Deisenhammer; Joep Killestein; Ingrid E Lundberg; Jiri Vencovsky; Mike T Nurmohamed; Dirkjan van Schaardenburg; Irene E M Bultink; Alexandre E Voskuyl; D Michiel Pegtel; Conny J van der Laken; Johannes W J Bijlsma; Cornelis L Verweij Journal: Arthritis Res Ther Date: 2016-02-17 Impact factor: 5.156